Shares of Dyax Corp. (DYAX) were up more than 49% in extended trading on Tuesday, following positive results from the company’s phase 1b clinical trial of DX-2930, which is being developed for the prevention of hereditary angioedema attacks.
Forex – financial instrument.Forex news
Shares of Dyax Corp. (DYAX) were up more than 49% in extended trading on Tuesday, following positive results from the company’s phase 1b clinical trial of DX-2930, which is being developed for the prevention of hereditary angioedema attacks.